Veenat 400 mg Tablet contains Imatinib mesylate, a targeted therapy used to treat certain cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). By inhibiting specific proteins responsible for cancer cell growth, it helps manage these conditions effectively. For more details, see Mayo Clinic, Drugs.com, FDA, and WebMD.
Key Benefits & Uses
-
Chronic Myeloid Leukemia (CML): Targets and inhibits the abnormal BCR-ABL protein, reducing cancer cell proliferation (Healthline, PubMed).
-
Gastrointestinal Stromal Tumors (GIST): Inhibits KIT and PDGFRα receptors, slowing tumor growth (WHO).
-
Dermatofibrosarcoma Protuberans (DFSP): Effective in treating this rare skin cancer (Drugs.com).
-
Myelodysplastic Syndromes (MDS): Improves blood cell production in certain cases (Mayo Clinic).
How to Use
-
Dosage: Typically, 400 mg once daily (Mayo Clinic).
-
Administration: Take with food and a full glass of water to minimize stomach irritation (Drugs.com).
-
Alternative Method: If swallowing is difficult, dissolve the tablet in approximately 200 ml of water or apple juice, stir, and consume immediately (Drugs.com).
Important Safety Information
-
Pregnancy & Breastfeeding: Not recommended during pregnancy or breastfeeding due to potential harm to the fetus or infant (WebMD).
-
Liver/Kidney Impairment: Use with caution; dose adjustments may be necessary (FDA).
-
Drug Interactions: Avoid grapefruit juice; it may increase blood levels of Imatinib (Healthline).
-
Monitoring: Regular blood tests are recommended to monitor liver function and blood cell counts (PubMed).
Common Side Effects
-
Common: Nausea, vomiting, diarrhea, muscle cramps, fatigue, rash, and abdominal pain (WebMD).
-
Serious: Fluid retention, liver problems, and increased risk of infections (Drugs.com).
Why Choose Veenat 400 mg
-
Proven Efficacy: Demonstrated effectiveness in treating CML, GIST, and other cancers (Mayo Clinic).
-
Convenient Dosage: Once-daily administration with food (Drugs.com).
-
Established Safety Profile: Extensive clinical experience and monitoring guidelines (FDA).

